Expectations trend
FY2028 · fiscal year ending 2028-06-30 · fmp
iBio Inc (IBIO)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$0.73-8.74%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for IBIO yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Advance clinical trial dosing in 2Q 2026 | iBio plans to start clinical trial dosing in 2Q 2026. | Intact | Dosing not initiated by end of 2Q 2026 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-06-30 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 11, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
IBIO is a high-risk clinical-stage biotechnology story, with value tied more to future program potential than current earnings. Its long-term thesis is in a watch state: development milestones are progressing, but recent financial performance is weak and management is rated volatile.
The valuation model has low confidence and points to a premium versus peers, while its expectations gap is near the top of the measured range. That combination suggests expectations may be demanding relative to the evidence, though the model attributes the difference to potential from the pipeline and reports low valuation fragility.
Near term, the company remains loss-making, and its recent financial performance sits well below its industry cohort; a smaller-company, high-miss-rate profile also raises the chance of a weak report. Over the multi-year view, IBIO-600 dosing has broadly followed the stated plan, while IBIO-610 and IBIO-800 have advanced through earlier development stages, though execution and clinical outcomes remain uncertain.
The thesis depends on continued clinical progress, including planned IBIO-600 dose escalation and progress toward first-in-human testing for IBIO-610. A guidance cut would be a meaningful negative; broader Healthcare-sector strength could help sentiment, but that is a sector backdrop rather than proof of company progress.
Over the next 1 to 3 years, IBIO offers pipeline potential alongside high clinical, financial, and execution risk, with current fundamentals providing limited support for confidence in the long-term thesis. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| The company aims to manage losses and cash burn while developing programs. |
| Broken |
| Operating loss exceeds negative $8.37 million in 2026-Q3 |
Operating income: $-16.383M FY2026-Q4; GAAP. Published target: Operating loss no worse than negative $8.37 million in 2026-Q3. The stored target says 2026-Q3; this source reports FY2026-Q4. Fiscal/calendar alignment needs review. Aug 28, 2026-16,383,000 USD · source valueLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 1 of 2 supplied quarters. Management reported: “Financial Results: Revenues for the fiscal year ended June 30, 2026, were approximately $0.1 million, a decrease of $0.3 million over the $0.4 million in revenue for the fiscal year 2025.” Delivery assessment Nov 5, 2026 |
Stabilize and grow revenue after sharp decline | A primary condition in iBio Inc's published investment case. The stated target is Revenue decline less than 72% in next 12 months. | Intact | Revenue decline exceeds 72% in next 12 months | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 5, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.40 → $-0.59 · observed estimates
$0.00B → $0.00B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.40 | $125,000 | 2 / 4 |
| 2026-07-25 | $-0.40 | $125,000 | 2 / 4 |
| 2026-07-26 | $-0.40 | $125,000 | 2 / 4 |
| 2026-07-27 | $-0.40 | $125,000 | 2 / 4 |
| 2026-07-28 | $-0.40 | $125,000 | 2 / 4 |
| 2026-07-29 | $-0.40 | $125,000 | 2 / 4 |
| 2026-07-30 | $-0.40 | $125,000 | 2 / 4 |
| 2026-07-31 | $-0.40 | $125,000 | 2 / 4 |
| 2026-08-01 | $-0.40 | $125,000 | 2 / 4 |
| 2026-08-02 | $-0.40 | $125,000 | 2 / 4 |
| 2026-08-03 | $-0.40 | $125,000 | 2 / 4 |
| 2026-08-04 | $-0.40 | $125,000 | 2 / 4 |
| 2026-08-05 | $-0.40 | $125,000 | 2 / 4 |
| 2026-08-06 | $-0.40 | $125,000 | 2 / 4 |
| 2026-08-07 | $-0.40 | $125,000 | 2 / 4 |
| 2026-08-08 | $-0.40 | $125,000 | 2 / 4 |
| 2026-08-09 | $-0.40 | $125,000 | 2 / 4 |
| 2026-08-10 | $-0.40 | $125,000 | 2 / 4 |
| 2026-08-12 | $-0.40 | $125,000 | 2 / 4 |
| 2026-08-13 | $-0.40 | $125,000 | 2 / 4 |
| 2026-08-14 | $-0.40 | $125,000 | 2 / 4 |
| 2026-08-15 | $-0.40 | $125,000 | 2 / 4 |
| 2026-08-16 | $-0.40 | $125,000 | 2 / 4 |
| 2026-08-17 | $-0.40 | $125,000 | 2 / 4 |
| 2026-08-18 | $-0.40 | $125,000 | 2 / 4 |
| 2026-08-19 | $-0.40 | $125,000 | 2 / 4 |
| 2026-08-20 | $-0.40 | $125,000 | 2 / 4 |
| 2026-08-21 | $-0.40 | $125,000 | 2 / 4 |
| 2026-08-22 | $-0.40 | $125,000 | 2 / 4 |
| 2026-08-23 | $-0.40 | $125,000 | 2 / 4 |
| 2026-08-24 | $-0.40 | $125,000 | 2 / 4 |
| 2026-08-25 | $-0.40 | $125,000 | 2 / 4 |
| 2026-08-26 | $-0.40 | $125,000 | 2 / 4 |
| 2026-08-27 | $-0.40 | $125,000 | 2 / 4 |
| 2026-08-28 | $-0.40 | $125,000 | 2 / 4 |
| 2026-08-29 | $-0.40 | $125,000 | 2 / 4 |
| 2026-08-30 | $-0.34 | $125,000 | 3 / 4 |
| 2026-08-31 | $-0.34 | $125,000 | 3 / 4 |
| 2026-09-01 | $-0.43 | $25,000 | 3 / 4 |
| 2026-09-02 | $-0.43 | $25,000 | 3 / 4 |
| 2026-09-03 | $-0.43 | $25,000 | 3 / 4 |
| 2026-09-04 | $-0.43 | $25,000 | 3 / 4 |
| 2026-09-05 | $-0.43 | $25,000 | 3 / 4 |
| 2026-09-06 | $-0.43 | $25,000 | 3 / 4 |
| 2026-09-07 | $-0.43 | $25,000 | 3 / 4 |
| 2026-09-08 | $-0.43 | $25,000 | 3 / 4 |
| 2026-09-09 | $-0.43 | $25,000 | 3 / 4 |
| 2026-09-10 | $-0.43 | $25,000 | 3 / 4 |
| 2026-09-11 | $-0.58 | $25,000 | 3 / 4 |
| 2026-09-12 | $-0.58 | $25,000 | 3 / 4 |
| 2026-09-13 | $-0.58 | $25,000 | 3 / 4 |
| 2026-09-14 | $-0.58 | $25,000 | 3 / 4 |
| 2026-09-15 | $-0.58 | $25,000 | 3 / 4 |
| 2026-09-16 | $-0.58 | $25,000 | 3 / 4 |
| 2026-09-17 | $-0.58 | $25,000 | 3 / 4 |
| 2026-09-18 | $-0.58 | $25,000 | 3 / 4 |
| 2026-09-19 | $-0.59 | $20,000 | 3 / 4 |
| 2026-09-20 | $-0.59 | $20,000 | 4 / 5 |
| 2026-09-21 | $-0.59 | $20,000 | 4 / 5 |
| 2026-09-22 | $-0.59 | $20,000 | 4 / 5 |
| 2026-09-23 | $-0.59 | $20,000 | 4 / 5 |
| 2026-09-24 | $-0.59 | $20,000 | 4 / 5 |
| 2026-09-25 | $-0.59 | $20,000 | 4 / 5 |
| 2026-09-26 | $-0.59 | $20,000 | 4 / 5 |
| 2026-09-27 | $-0.59 | $20,000 | 4 / 5 |
| 2026-09-28 | $-0.59 | $20,000 | 4 / 5 |
| 2026-09-29 | $-0.59 | $20,000 | 4 / 5 |
| 2026-09-30 | $-0.59 | $20,000 | 4 / 5 |
| 2026-10-01 | $-0.59 | $20,000 | 4 / 5 |
| 2026-10-02 | $-0.59 | $20,000 | 4 / 5 |
| 2026-10-03 | $-0.59 | $20,000 | 4 / 5 |
| 2026-10-04 | $-0.59 | $20,000 | 4 / 5 |
| 2026-10-05 | $-0.59 | $20,000 | 4 / 5 |
| 2026-10-06 | $-0.59 | $20,000 | 4 / 5 |
| 2026-10-07 | $-0.59 | $20,000 | 4 / 5 |
| 2026-10-08 | $-0.59 | $20,000 | 4 / 5 |
| 2026-10-09 | $-0.59 | $20,000 | 4 / 5 |
| 2026-10-10 | $-0.59 | $20,000 | 4 / 5 |
| 2026-10-11 | $-0.59 | $20,000 | 4 / 5 |
| 2026-10-12 | $-0.59 | $20,000 | 4 / 5 |
| 2026-10-13 | $-0.59 | $20,000 | 4 / 5 |
| 2026-10-14 | $-0.59 | $20,000 | 4 / 5 |
| 2026-10-15 | $-0.59 | $20,000 | 4 / 5 |
| 2026-10-16 | $-0.59 | $20,000 | 4 / 5 |
| 2026-10-17 | $-0.59 | $20,000 | 4 / 5 |
| 2026-10-18 | $-0.59 | $20,000 | 4 / 5 |
| 2026-10-19 | $-0.59 | $20,000 | 4 / 5 |
| 2026-10-20 | $-0.59 | $20,000 | 4 / 5 |
| 2026-10-21 | $-0.59 | $20,000 | 4 / 5 |
| 2026-10-22 | $-0.59 | $20,000 | 4 / 5 |
| 2026-10-23 | $-0.59 | $20,000 | 4 / 5 |
| 2026-10-24 | $-0.59 | $20,000 | 4 / 5 |
| 2026-10-25 | $-0.59 | $20,000 | 4 / 5 |
| 2026-10-26 | $-0.59 | $20,000 | 4 / 5 |
| 2026-10-27 | $-0.59 | $20,000 | 4 / 5 |
| 2026-10-28 | $-0.59 | $20,000 | 4 / 5 |
| 2026-10-29 | $-0.59 | $20,000 | 4 / 5 |
| 2026-10-30 | $-0.59 | $20,000 | 4 / 5 |
| 2026-10-31 | $-0.59 | $20,000 | 4 / 5 |
| 2026-11-01 | $-0.59 | $20,000 | 4 / 5 |
| 2026-11-02 | $-0.59 | $20,000 | 4 / 5 |
| 2026-11-03 | $-0.59 | $20,000 | 4 / 5 |
| 2026-11-04 | $-0.59 | $20,000 | 4 / 5 |
| 2026-11-05 | $-0.59 | $20,000 | 4 / 5 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 9 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 7–Nov 5 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 7, 2026–Nov 5, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.